The Outperformers (51-60)
These companies have been ranked based on their stock's excess return over the Sensex for a five-year period
September 03, 2019
With a powerful client base and an all-in-one package, the contract R&D firm Syngene is galloping ahead and now even into manufacturing
Shruti Venkatesh - May 17, 2019
By focusing on its strength in manufacturing lyophilized injectables, Gufic Biosciences has made a strong comeback and wants to aggressively push into the EU market next
Jash Kriplani - April 16, 2018
Is the worst over for pharma stocks?
The pharma index has hugely underperformed the Sensex in CY17 owing to regulatory overhang and FDA issues
July 17, 2017
Under The Weather- Part 1
The domestic pharma industry, which is already battling the US FDA, has now to contend with regulatory challenges at home
Krishna Gopalan - May 20, 2017
Under The Weather - Part 2
Even as it battles the US FDA, the industry has been caught off-guard by policy changes back home
Krishna Gopalan - June 05, 2017
One giant leap for Mankind
Mankind Pharma made it big in small towns, but can its magic help it conquer the bigger markets?
Himanshu Kakkar - January 21, 2016
Will Sun rise again?
Can Sun Pharma’s Dilip Shanghvi work his merger magic on Ranbaxy?
Kripa Mahalingam - June 15, 2015
Nephroplus’ Vikram Vuppala’s eight-wheelers can outrun any fancy car
Aditi Saxena - June 17, 2015
"If you believe in something, have the courage to take it to completion"
The Piramal group head on how his values have helped him make bold business decisions
N Mahalakshmi - December 21, 2015